Cerevel Therapeutics (Nasdaq: CERE) relentlessly finds paths through complexity to bring real progress and new treatment options to people living with a broad range of neurological and neuropsychiatric disorders.
Cerevel is developing its most advanced therapeutic candidate, tavapadon, for the treatment of both early- and late-stage Parkinson’s disease. Tavapadon was rationally designed as an orally-bioavailable, once-daily partial agonist that selectively targets dopamine D1/D5 receptor subtypes with the goal of balancing meaningful motor activity with a favorable tolerability profile. Cerevel’s second most advanced therapeutic candidate, CVL-865, is being developed for the treatment of both epilepsy and anxiety. CVL-865 was rationally designed as an orally-bioavailable, twice-daily positive allosteric modulator that selectively targets GABAA receptors containing alpha-2/3/5 subunits. Cerevel is also developing CVL-231 for the treatment of psychosis. CVL-231 was rationally designed as a positive allosteric modulator that selectively targets the muscarinic acetylcholine 4 receptor (M4) subtype to harness the anti-psychotic benefit believed to be associated with M4 while minimizing the side effects typically associated with pan-muscarinic agonists.
Cerevel Therapeutics was founded in 2018 as a partnership between Bain Capital Life Sciences, Bain Capital Private Equity, and Pfizer to build a new, fully-integrated biopharmaceutical company focused on advancing a broad portfolio of medicines for central nervous system disorders. Both Bain Capital Life Sciences and Bain Capital Private Equity are represented on the Company’s Board of Directors.
Bain Capital Healthcare
We have built one of the largest and deepest healthcare investing teams in the world. Click here to read more about the breadth and legacy of our efforts.